Antibodies to TGF-beta
US10174108B2 · kind B2 · utility
0Cited by
8References
18Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Sep 28, 2016 |
| Grant date | Jan 8, 2019 |
| Priority date | — |
| Expiry date | Oct 18, 2036 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/92
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to antibody molecules, in particular antibody molecules that bind. Transforming Growth Factor beta (TGFβ), and uses thereof. More particularly, the invention relates to antibody molecules that bind and preferably neutralize TGFβ1, TGFβ2 and TGFβ3, so-called “pan-specific” antibody molecules, and uses of such antibody molecules. Preferred embodiments within the present invention are antibody molecules, whether whole antibody (e.g. IgG, such as IgG1 or IgG4) or antibody fragments (e.g. scFv, Fab, dAb).
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.